Today: 21 May 2026
Browse Category

OTC:CRWE 30 September 2025

Crown Electrokinetics (CRWV/CRKN) Surges Amid Takeover Buzz – Key Facts & Analysis (Sept 30, 2025)

Crown Equity Holdings (OTC:CRWE) Surges Into Spotlight: Joint Ventures Spark Speculation – Stock Update (1:20 PM ET Sept 2025)

Crown Equity Holdings (CRWE), an OTC-pink microcap with a $15–16 million market cap, reported $1,440 in 2024 revenue and a $3.72 million net loss. The stock trades near its 52-week low with negligible daily volume and no analyst coverage. In September 2025, CRWE announced joint venture LOIs with BioHarvest Naturals and Stewart Holdings. Ahmad Moradi became board chairman in June 2024.
30 September 2025
·

Stock Market Today

  • Nvidia (NVDA) Reports Strong Q1 2026 with Revenue Surging 85% and Robust Guidance
    May 20, 2026, 6:31 PM EDT. Nvidia (NASDAQ:NVDA) delivered an 85.2% year-on-year revenue increase to $81.62 billion in Q1 CY2026, beating analyst expectations by 3.5%. Its adjusted earnings per share of $1.87 also surpassed forecasts by 5.4%. The company's non-GAAP EBITDA margin rose to 69.2%, supported by operating margins climbing to 65.6% from 49.1% a year ago. Nvidia provided Q2 revenue guidance of $91 billion, 5.7% above consensus, signaling accelerating demand amid growth in AI infrastructure. CEO Jensen Huang highlighted the rapid expansion of AI factories as a key growth driver. The firm's five-year compounded annual revenue growth rate sits at 67.4%, with recent acceleration reflecting strong market positioning in semiconductors, despite cyclical industry risks.

Latest articles

EnerSys Stock Just Reversed After Earnings—The Guidance Beat Traders Wanted

EnerSys Stock Just Reversed After Earnings—The Guidance Beat Traders Wanted

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
AEVEX Stock Jumps After Hours as Drone Maker Posts 307% Revenue Surge and New Air Force Deal

AEVEX Stock Jumps After Hours as Drone Maker Posts 307% Revenue Surge and New Air Force Deal

21 May 2026
AEVEX Corp. shares surged over 10% after hours Wednesday following a first-quarter profit of $21 million and new U.S. Air Force contracts worth $15.6 million. Revenue jumped to $216.7 million, beating estimates. The company, which went public in April, raised its full-year revenue outlook to $600–$620 million. The stock had closed regular trading at $26.27, down 0.23%.
Go toTop